About Us:

Our Hematology/Oncology department is currently seeking a physician specializing in Leukemia or Bone Marrow who is interested in spearheading clinical research within an academic-based practice. Tulane Cancer Center is an emerging NCI-designated comprehensive cancer center whose purposes are the treatment and control of cancer, the advancement of biomedical knowledge through laboratory and clinical research, and the training of physicians, scientists, and other healthcare workers. 

About the Role:

We encourage our incoming physicians to advance their academic careers by collaborating with bench researchers, leading clinical trials, and publishing as primary authors for translational clinical research.

• Physicians will focus on Leukemia or Bone Marrow while being the leader in innovative research trials 
• You will receive APP support to assist with clinic and inpatient rounding
• Responsible for teaching fellows, residents, and medical students within our multi-disciplinary program
• There will be at least 50% protected time for incoming faculty

Research and Clinical Trials:

This position offers an unprecedented opportunity to lead research that is truly pioneering within the field. You will have the chance to position yourself at the forefront of your discipline, contributing to your curriculum vitae and opening doors for future research and academic appointments. 

Trial 1: Phase III study comparing two treatment arms in Acute Myeloid Leukemia (AML) patients who have failed 2-4 previous induction therapies. Focus on relapsed or refractory cases, with a 1:1 enrollment ratio.

Trial 2: Compares LOXO-305 against idelalisib plus rituximab or bendamustine plus rituximab in previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), specifically those who have used a BTK inhibitor.

Trial 3: Evaluates the efficacy of blinatumomab in treating CD19-positive mixed phenotypic acute leukemia (MPAL) in patients with relapsed/refractory or measurable residual disease (MRD).

Trial 4: Two-part study of venetoclax with AZA and CC-486 in dose confirmation and finding stages to establish the recommended Phase 3 dose for each combination.

Trial 5: Assesses the effectiveness of galinpepimut-S (GPS) versus best available therapy (BAT) in improving survival in Acute Myeloid Leukemia (AML) patients who are in their second or subsequent complete remission (CR2 or CRp2).

Location:

• Locate